Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015

S. A. McNeil; M. K. Andrew; L. Ye; F. Haguinet; T. F. Hatchette; M. Elsherif; J. Leblanc; A. Ambrose; A. McGeer; J. E. McElhaney; M. Loeb; D. Mackinnon-Cameron; R. Sharma; G. Dos Santos; V. Shinde

doi:10.2807/1560-7917.ES2015.20.5.21024

Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015

S. A. McNeil, M. K. Andrew, L. Ye, F. Haguinet, T. F. Hatchette, M. Elsherif, J. Leblanc, A. Ambrose, A. McGeer, J. E. McElhaney, M. Loeb, D. Mackinnon-Cameron, R. Sharma, G. Dos Santos, V. Shinde

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

48 Citas (Scopus)

Resumen

The 2014/15 influenza season in Canada has been characterised to date by early and intense activity dominated by influenza A(H3N2). A total of 99.0% (593/599) hospitalisations for laboratory-confirmed influenza with a known influenza virus type enrolled in sentinel hospitals of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network were due to influenza A. Of the 216 with a known subtype, influenza A(H3N2) accounted for 99.1% (n=214). Interim unmatched vaccine effectiveness (VE) estimates adjusted for age and presence of one or more medical comorbidities were determined by test-negative case-control design to be -16.8% (90% confidence interval (CI): -48.9 to 8.3) overall and -22.0% (90% CI: -66.5 to 10.7) for laboratory-confirmed influenza A(H3N2). Among adults aged under 65 years, the overall VE was 10.8% (90% CI: -50.2 to 47.0) while in adults aged 65 years or older, the overall VE was -25.4% (90% CI: -65.0 to 4.6).

Idioma original	English
Páginas (desde-hasta)	1-7
Número de páginas	7
Publicación	Eurosurveillance
Volumen	20
N.º	5
DOI	https://doi.org/10.2807/1560-7917.ES2015.20.5.21024
Estado	Published - 2015

ASJC Scopus Subject Areas

Epidemiology
Public Health, Environmental and Occupational Health
Virology

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.2807/1560-7917.ES2015.20.5.21024

Otros archivos y enlaces

Huella

Profundice en los temas de investigación de 'Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015'. En conjunto forman una huella única.

Citar esto

McNeil, S. A., Andrew, M. K., Ye, L., Haguinet, F., Hatchette, T. F., Elsherif, M., Leblanc, J., Ambrose, A., McGeer, A., McElhaney, J. E., Loeb, M., Mackinnon-Cameron, D., Sharma, R., Dos Santos, G., & Shinde, V. (2015). Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015. Eurosurveillance, 20(5), 1-7. https://doi.org/10.2807/1560-7917.ES2015.20.5.21024

Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015. / McNeil, S. A.; Andrew, M. K.; Ye, L. et al.
En: Eurosurveillance, Vol. 20, N.º 5, 2015, p. 1-7.

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

McNeil, SA, Andrew, MK, Ye, L, Haguinet, F, Hatchette, TF, Elsherif, M, Leblanc, J, Ambrose, A, McGeer, A, McElhaney, JE, Loeb, M, Mackinnon-Cameron, D, Sharma, R, Dos Santos, G & Shinde, V 2015, 'Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015', Eurosurveillance, vol. 20, n.º 5, pp. 1-7. https://doi.org/10.2807/1560-7917.ES2015.20.5.21024

McNeil SA, Andrew MK, Ye L, Haguinet F, Hatchette TF, Elsherif M et al. Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015. Eurosurveillance. 2015;20(5):1-7. doi: 10.2807/1560-7917.ES2015.20.5.21024

@article{3b1b4e5fb00447e49c4cc69efaa51ef7,

title = "Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015",

abstract = "The 2014/15 influenza season in Canada has been characterised to date by early and intense activity dominated by influenza A(H3N2). A total of 99.0% (593/599) hospitalisations for laboratory-confirmed influenza with a known influenza virus type enrolled in sentinel hospitals of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network were due to influenza A. Of the 216 with a known subtype, influenza A(H3N2) accounted for 99.1% (n=214). Interim unmatched vaccine effectiveness (VE) estimates adjusted for age and presence of one or more medical comorbidities were determined by test-negative case-control design to be -16.8% (90% confidence interval (CI): -48.9 to 8.3) overall and -22.0% (90% CI: -66.5 to 10.7) for laboratory-confirmed influenza A(H3N2). Among adults aged under 65 years, the overall VE was 10.8% (90% CI: -50.2 to 47.0) while in adults aged 65 years or older, the overall VE was -25.4% (90% CI: -65.0 to 4.6).",

author = "McNeil, {S. A.} and Andrew, {M. K.} and L. Ye and F. Haguinet and Hatchette, {T. F.} and M. Elsherif and J. Leblanc and A. Ambrose and A. McGeer and McElhaney, {J. E.} and M. Loeb and D. Mackinnon-Cameron and R. Sharma and {Dos Santos}, G. and V. Shinde",

year = "2015",

doi = "10.2807/1560-7917.ES2015.20.5.21024",

language = "English",

volume = "20",

pages = "1--7",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "Centre Europeen pour la Surveillance Epidemiologique du SIDA",

number = "5",

}

TY - JOUR

T1 - Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015

AU - McNeil, S. A.

AU - Andrew, M. K.

AU - Ye, L.

AU - Haguinet, F.

AU - Hatchette, T. F.

AU - Elsherif, M.

AU - Leblanc, J.

AU - Ambrose, A.

AU - McGeer, A.

AU - McElhaney, J. E.

AU - Loeb, M.

AU - Mackinnon-Cameron, D.

AU - Sharma, R.

AU - Dos Santos, G.

AU - Shinde, V.

PY - 2015

Y1 - 2015

N2 - The 2014/15 influenza season in Canada has been characterised to date by early and intense activity dominated by influenza A(H3N2). A total of 99.0% (593/599) hospitalisations for laboratory-confirmed influenza with a known influenza virus type enrolled in sentinel hospitals of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network were due to influenza A. Of the 216 with a known subtype, influenza A(H3N2) accounted for 99.1% (n=214). Interim unmatched vaccine effectiveness (VE) estimates adjusted for age and presence of one or more medical comorbidities were determined by test-negative case-control design to be -16.8% (90% confidence interval (CI): -48.9 to 8.3) overall and -22.0% (90% CI: -66.5 to 10.7) for laboratory-confirmed influenza A(H3N2). Among adults aged under 65 years, the overall VE was 10.8% (90% CI: -50.2 to 47.0) while in adults aged 65 years or older, the overall VE was -25.4% (90% CI: -65.0 to 4.6).

AB - The 2014/15 influenza season in Canada has been characterised to date by early and intense activity dominated by influenza A(H3N2). A total of 99.0% (593/599) hospitalisations for laboratory-confirmed influenza with a known influenza virus type enrolled in sentinel hospitals of the Serious Outcomes Surveillance Network of the Canadian Immunization Research Network were due to influenza A. Of the 216 with a known subtype, influenza A(H3N2) accounted for 99.1% (n=214). Interim unmatched vaccine effectiveness (VE) estimates adjusted for age and presence of one or more medical comorbidities were determined by test-negative case-control design to be -16.8% (90% confidence interval (CI): -48.9 to 8.3) overall and -22.0% (90% CI: -66.5 to 10.7) for laboratory-confirmed influenza A(H3N2). Among adults aged under 65 years, the overall VE was 10.8% (90% CI: -50.2 to 47.0) while in adults aged 65 years or older, the overall VE was -25.4% (90% CI: -65.0 to 4.6).

UR - http://www.scopus.com/inward/record.url?scp=84922771275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922771275&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES2015.20.5.21024

DO - 10.2807/1560-7917.ES2015.20.5.21024

M3 - Article

C2 - 602268033

AN - SCOPUS:84922771275

SN - 1025-496X

VL - 20

SP - 1

EP - 7

JO - Eurosurveillance

JF - Eurosurveillance

IS - 5

ER -